Commercially available assays for multiplex detection of alpha human papillomaviruses

References

• Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology401(1), 70–79 (2010).
   PubMed Web of Science ®Google Scholar
• Burk RD. Nomenklatura. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3–8 July 2010.
   Google Scholar
• Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer DOI: 10.1002/ijc.25396 (2010) (Epub ahead of print).
   Google Scholar
• Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin. Otolaryngol.31(4), 259–266 (2006).
   PubMed Web of Science ®Google Scholar
• De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int. J. Cancer124(7), 1626–1636 (2009).
   PubMed Web of Science ®Google Scholar
• Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control.20(4), 449–457 (2009).
   PubMed Web of Science ®Google Scholar
• Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer121(3), 621–632 (2007).
   PubMed Web of Science ®Google Scholar
• Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet. Gynecol.113(4), 917–924 (2009).
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Tortolero-Luna G, Ferrer E et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine26(Suppl. 10), K17–K28 (2008).
   PubMed Web of Science ®Google Scholar
• Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect. Agent Cancer4, 8 (2009).
   PubMedGoogle Scholar
• Wentzensen N, Schiffman M, Dunn T et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int. J. Cancer125(9), 2151–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Impact of improved classification on the association of human papillomavirus with cervical precancer. Am. J. Epidemiol.171(2), 155–163 (2010).
   PubMedGoogle Scholar
• Bouvard V, Baan R, Straif K et al. A review of human carcinogens – Part B: biological agents. Lancet Oncol.10(4), 321–322 (2009).
   PubMed Web of Science ®Google Scholar
• Muñoz N, Bosch FX, de Sanjosé S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med.348(6), 518–527 (2003).
   PubMed Web of Science ®Google Scholar
• Muñoz N, Bosch FX, Castellsagué X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer111(2), 278–285 (2004).
   PubMed Web of Science ®Google Scholar
• Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infections. J. Clin. Virol.32(Suppl. 1), S43–S51 (2005).
   Web of Science ®Google Scholar
• Coutlée F, Mayrand MH, Roger M, Franco EL. Detection and typing of human papillomavirus nucleic acids in biological fluids. Public Health Genomics12(5–6), 308–318 (2009).
   PubMedGoogle Scholar
• Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis. Markers23(4), 273–281 (2007).
   PubMed Web of Science ®Google Scholar
• Snijders PJ, Heideman DA, Meijer CJ. Methods for HPV detection in exfoliated cell and tissue specimens. APMIS118(6–7), 520–528 (2010).
   PubMed Web of Science ®Google Scholar
• Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J. Clin. Microbiol.35(3), 791–795 (1997).
   PubMed Web of Science ®Google Scholar
• van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J. Clin. Microbiol.40(3), 779–787 (2002).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine26(Suppl. 10), K29–K41 (2008).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer119(5), 1095–1101 (2006).
   PubMed Web of Science ®Google Scholar
• Cox JT. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J. Clin. Virol.45(Suppl. 1), S3–S12 (2009).
   Google Scholar
• Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ. Validation of high-risk HPV tests for primary cervical screening. J. Clin. Virol.46(Suppl. 3), S1–S4 (2009).
   PubMedGoogle Scholar
• Meijer CJ, Berkhof J, Castle PE et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer124(3), 516–520 (2009).
   PubMed Web of Science ®Google Scholar
• Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine24(Suppl. 3), 78–89 (2006).
   Web of Science ®Google Scholar
• Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening? Int. J. Cancer125(11), 2489–2496 (2009).
   PubMed Web of Science ®Google Scholar
• Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol. Oncol.104(1), 232–246 (2007).
   PubMed Web of Science ®Google Scholar
• Poljak M, Marin IJ, Seme K, Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high risk cocktail. J. Clin. Virol.25(Suppl. 3), S89–S97 (2002).
   PubMed Web of Science ®Google Scholar
• Seme K, Fujs K, Kocjan BJ, Poljak M. Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J. Virol. Methods134(1–2), 252–256 (2006).
   PubMed Web of Science ®Google Scholar
• Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. Human papillomavirus genotype specificity of Hybrid Capture 2. J. Clin. Microbiol.46(8), 2595–2604 (2008).
   PubMed Web of Science ®Google Scholar
• Schutzbank TE, Jarvis C, Kahmann N, Lopez K, Weimer M, Yount A. Detection of high-risk papillomavirus DNA with commercial invader-technology-based analytespecific reagents following automated extraction of DNA from cervical brushings in ThinPrep media. J. Clin. Microbiol.45(12), 4067–4069 (2007).
   PubMedGoogle Scholar
• Wright TC Jr, Massad LS, Dunton CJ et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol.197(4), 346–355 (2007).
   PubMed Web of Science ®Google Scholar
• Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ. Crosssectional comparison of an automated Hybrid Capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J. Clin. Microbiol.44(10), 3680–3685 (2006).
   PubMedGoogle Scholar
• Poljak M, Kocjan BJ, Kovanda A et al. Human papillomavirus genotype specificity of hybrid capture 2 low-risk probe cocktail. J. Clin. Microbiol.47(8), 2611–2615 (2009).
   PubMedGoogle Scholar
• Szarewski A, Ambroisine L, Cadman L et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev.17(11), 3033–3042 (2008).
   PubMed Web of Science ®Google Scholar
• Sargent A, Bailey A, Turner A et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J. Clin. Microbiol.48(2), 554–558 (2010).
   PubMedGoogle Scholar
• Eder PS, Lou J, Huff J, Macioszek J. The next-generation Hybrid Capture High-Risk HPV DNA assay on a fully automated platform. J. Clin. Virol.45(Suppl. 1), S85–S92 (2009).
   PubMedGoogle Scholar
• Day SP, Hudson A, Mast A et al. Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study. J. Clin. Virol.45(Suppl. 1), S63–S72 (2009).
   Google Scholar
• Stillman MJ, Day SP, Schutzbank TE. A comparative review of laboratory-developed tests utilizing Invader HPV analyte-specific reagents for the detection of high-risk human papillomavirus. J. Clin. Virol.45(Suppl. 1), S73–S77 (2009).
   Google Scholar
• Wong AK, Chan RC, Nichols WS, Bose S. Human papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay. J. Clin. Microbiol.46(3), 869–875 (2008).
   PubMedGoogle Scholar
• Ginocchio CC, Barth D, Zhang F. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA. J. Clin. Microbiol.46(5), 1641–1646 (2008).
   PubMedGoogle Scholar
• Harvey M, Stout S, Starkey CR, Hendren R, Holt S, Miller GC. The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection. J. Clin. Virol.45(Suppl. 1), S79–S83 (2009).
   PubMedGoogle Scholar
• Johnson LR, Starkey CR, Palmer J et al. A comparison of two methods to determine the presence of high-risk HPV cervical infections. Am. J. Clin. Pathol.130(3), 401–408 (2008).
   PubMedGoogle Scholar
• Kurtycz DF, Smith M, He R, Miyazaki K, Shalkham J. Comparison of methods trial for high-risk HPV. Diagn. Cytopathol.38(2), 104–108 (2010).
   PubMedGoogle Scholar
• Einstein MH, Martens MG, Garcia FA et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol. Oncol.118(2), 116–122 (2010).
   PubMedGoogle Scholar
• Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am. J. Clin. Pathol.134(2), 193–199 (2010).
   PubMed Web of Science ®Google Scholar
• Poljak M, Fujs K, Seme K, Kocjan BJ, Vrtačnik-Bokal E. Retrospective and prospective evaluation of the Amplicor HPV test for detection of 13 high-risk human papillomavirus genotypes on 862 clinical samples. Acta Dermatovenerol. Alp. Pannon. Adriat.14(4), 147–152 (2005).
   PubMedGoogle Scholar
• van Ham MA, Bakkers JM, Harbers GK, Quint WG, Massuger LF, Melchers WJ. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J. Clin. Microbiol.43(6), 2662–2667 (2005).
   PubMed Web of Science ®Google Scholar
• Sandri MT, Lentati P, Benini E et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol.44(6), 2141–2146 (2006).
   PubMed Web of Science ®Google Scholar
• Stevens MP, Rudland E, Garland SM, Tabrizi SN. Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J. Clin. Microbiol.44(7), 2428–2433 (2006).
   PubMedGoogle Scholar
• Carozzi F, Bisanzi S, Sani C et al. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J. Clin. Microbiol.45(2), 364–369 (2007).
   PubMedGoogle Scholar
• Halfon P, Trepo E, Antoniotti G et al. Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high risk HPV genotypes in atypical squamous cells of unceirtain significance. J. Clin. Microbiol.45(2), 313–316 (2007).
   PubMed Web of Science ®Google Scholar
• Stevens MP, Garland SM, Rudland E, Tan J, Quinn MA, Tabrizi SN. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J. Clin. Microbiol.45(7), 2130–2137 (2007).
   PubMedGoogle Scholar
• Wahlstr öm C, Iftner T, Dillner J, Dillner L; Swedescreen study group. Population-based study of screening test performance indices of three human papillomavirus DNA tests. J. Med. Virol.79(8), 1169–1175 (2007).
   PubMedGoogle Scholar
• De Francesco MA, Gargiulo F, Schreiber C, Ciravolo G, Salinaro F, Manca N. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear. J. Virol. Methods147(1), 10–17 (2008).
   PubMedGoogle Scholar
• Mo LZ, Monnier-Benoit S, Kantelip B et al. Comparison of AMPLICOR and Hybrid Capture II assays for high-risk HPV detection in normal and abnormal liquied-based cytology: use of INNO-LiPA Genotyping assay to screeng the discordant results. J. Clin. Virol.41(2), 104–110 (2008).
   PubMedGoogle Scholar
• Wentzensen N, Gravitt PE, Solomon D, Wheeler CM, Castle PE. A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study. Cancer Epidemiol. Biomarkers Prev.18(5), 1341–1349 (2009).
   PubMedGoogle Scholar
• Monsonego J, Bohbot JM, Pollini G et al. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol. Oncol.99(1), 160–168 (2005).
   PubMed Web of Science ®Google Scholar
• Grisaru D, Avidor B, Niv J et al. Pilot study of prevalence of high-risk human papillomavirus genotypes in Israeli Jewish women referred for colposcopic examination. J. Clin. Microbiol.46(5), 1602–1605 (2008).
   PubMedGoogle Scholar
• Koidl C, Bozic M, Hadzisejdic I et al. Comparison of molecular assays for detection and typing of human papillomavirus. Am. J. Obstet. Gynecol.199(2), 144.e1–6 (2008).
   PubMedGoogle Scholar
• Gravitt PE, Coutlée F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cervical cancer screening. Vaccine.26(Suppl. 10), K42–K52 (2008).
   Google Scholar
• Qiao YL, Sellors JW, Eder PS et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol.9(10), 929–936 (2008).
   PubMed Web of Science ®Google Scholar
• Schlecht NF, Kulaga S, Robitaille J et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA286(24), 3106–3114 (2001).
   PubMed Web of Science ®Google Scholar
• Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst.97(14), 1072–1079 (2005).
   PubMed Web of Science ®Google Scholar
• Huang S, Tang N, Mak WB et al. Principles and analytical performance of Abbott RealTime HR HPV test. J. Clin. Virol.45(Suppl. 1), S13–S17 (2009).
   Google Scholar
• Poljak M, Kovanda A, Kocjan BJ, Seme K, Jancar N, Vrtacnik-Bokal E. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatovenerol. Alp. Panonica Adriat.18(3), 94–103 (2009).
   PubMedGoogle Scholar
• Tang N, Huang S, Erickson B et al. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. J. Clin. Virol.45(Suppl. 1), S25–S29 (2009).
   Google Scholar
• Huang S, Erickson B, Tang N et al. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J. Clin. Virol.45(Suppl. 1), S19–S23 (2009).
   Google Scholar
• Kaliterna V, Lepej SZ, Vince A. Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens. J. Med. Microbiol.58(12), 1662–1663 (2009).
   PubMedGoogle Scholar
• Cuzick J, Ambroisine L, Cadman L et al. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. J. Med. Virol.82(7), 1186–1191 (2010).
   PubMedGoogle Scholar
• Halfon P, Benmoura D, Agostini A et al. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. J. Clin. Virol.48(4), 246–250 (2010).
   PubMed Web of Science ®Google Scholar
• Castle PE, Sadorra M, Lau T, Aldrich C, Garcia FA, Kornegay J. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J. Clin. Microbiol.47(10), 3344–3347 (2009).
   PubMed Web of Science ®Google Scholar
• Wright T Jr, Sharma A, Gutekunst K et al. High Risk for >CIN2 in cobas4800 HPV 16/18 positive women >30 yrs with NILM cytology: ATHENA results. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3–8 July 2010.
   Google Scholar
• Stoler M, Sharma A, Gutekunst K et al. Cobas 4800 HPV Test Performance for >CIN2 and >CIN3 detection in women with ASC-US : ATHENA results. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3–8 July 2010.
   Google Scholar
• Lepej SZ, Grgić I, Poljak M et al. Detection of human papillomavirus genotypes 16/18/45 by hybrid capture hybridisation genotyping probe in clinical specimens: the first report. J. Clin. Virol.40(2), 171–172 (2007).
   PubMedGoogle Scholar
• Tiews S, Steinberg W, Schneider W, Hanrath C. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data. J. Clin. Virol.46(Suppl. 3), S11–S15 (2009).
   Google Scholar
• Hantz S, Decroisette E, Caly H et al. Testing of a new probe 16/18/45 Hybrid Capture (Digene) in women with high risk HPV infection. Pathol. Biol. (Paris)57(1), 81–85 (2009).
   PubMedGoogle Scholar
• Thai H, Rangwala S, Gay T et al. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology. J. Clin. Virol.45(Suppl. 1), S93–S97 (2009).
   Google Scholar
• Vince A, Lepej SZ. Diagnostic methods and techniques in cervical cancer prevention Part II: molecular diagnostics of HPV infection. Med. Glas. Ljek. komore Zenicko-doboj kantona7(1), 18–25 (2010).
   PubMedGoogle Scholar
• van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J. Clin. Microbiol.44(9), 3122–3129 (2006).
   PubMed Web of Science ®Google Scholar
• Feng Q, Cherne S, Winer RL et al. Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses. J. Clin. Microbiol.47(3), 547–553 (2009).
   PubMedGoogle Scholar
• Kleter B, van Doorn LJ, Schrauwen L et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol.37(8), 2508–2517 (1999).
   PubMed Web of Science ®Google Scholar
• Hesselink AT, van Ham MA, Heideman DA et al. Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J. Clin. Microbiol.46(10), 3215–3221 (2008).
   PubMed Web of Science ®Google Scholar
• Castle PE, Porras C, Quint WG et al. Comparison of two PCR-based human papillomavirus genotyping methods. J. Clin. Microbiol.46(10), 3437–3445 (2008).
   PubMed Web of Science ®Google Scholar
• Didelot-Rousseau MN, Courgnaud V, Nagot N et al. Comparison of INNO-LiPA HPV Genotyping v2 with PCR product subcloning and sequencing for identification of genital human papillomavirus genotypes in African women. J. Virol. Methods135(2), 181–185 (2006).
   PubMedGoogle Scholar
• Iftner T, Germ L, Swoyer R et al. Study comparing human papillomavirus (HPV) real-time multiplex PCR and Hybrid Capture II INNO-LiPA v2 HPV genotyping PCR assays. J. Clin. Microbiol.47(7), 2106–2113 (2009).
   PubMedGoogle Scholar
• Seme K, Lepej SZ, Lunar MM et al. Digene HPV Genotyping RH Test RUO: comparative evaluation with INNO-LiPA HPV Genotyping Extra Test for detection of 18 high-risk and probable high-risk human papillomavirus genotypes. J. Clin. Virol.46(2), 176–179 (2009).
   PubMedGoogle Scholar
• Gravitt PE, Peyton CL, Alessi TQ et al. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol.38(1), 357–361 (2000).
   PubMed Web of Science ®Google Scholar
• Greer CE, Wheeler CM, Manos MM. Sample preparation and PCR amplification from paraffin-embedded tissues. PCR Methods Appl.3(6), S113–S122 (1994).
   Google Scholar
• Coutlée F, Rouleau D, Ghattas G et al. Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. J. Clin. Microbiol.45(11), 3821–3823 (2007).
   PubMedGoogle Scholar
• Marks M, Gupta SB, Liaw KL et al. Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array using HPV52-specific TaqMan E6/E7 quantitative real-time PCR. J. Virol. Methods156(1–2), 152–156 (2009).
   PubMed Web of Science ®Google Scholar
• Stevens MP, Garland SM, Tabrizi SN. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J. Virol. Methods147(2), 290–296 (2008).
   PubMedGoogle Scholar
• Kocjan BJ, Poljak M, Seme K. Universal ProbeLibrary based real-time PCR assay for detection and confirmation of human papillomavirus genotype 52 infections. J. Virol. Methods163(2), 492–494 (2010).
   PubMedGoogle Scholar
• Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J. Virol. Methods156(1–2), 77–83 (2009).
   PubMedGoogle Scholar
• Halfon P, Benmoura D, Khiri H et al. Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck HPV-screening assay. J. Clin. Virol.47(1), 38–42 (2010).
   PubMedGoogle Scholar
• Schopp B, Holz B, Zago M et al. Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. J. Med. Virol.82(4), 605–615 (2010).
   PubMedGoogle Scholar
• Galan-Sanchez F, Rodriguez-Iglesias MA. Comparison of human papillomavirus genotyping using commercial assays based on PCR and reverse hybridization methods. APMIS117(10), 708–715 (2009).
   PubMedGoogle Scholar
• Liu SS, Leung RC, Chan KK, Cheung AN, Ngan HY. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay. J. Clin. Microbiol.48(3), 758–764 (2010).
   PubMed Web of Science ®Google Scholar
• Halfon P, Benmoura D, Agostini A et al. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. J. Clin. Virol.47(2), 177–181 (2010).
   PubMed Web of Science ®Google Scholar
• Geraets DT, Heideman DA, de Koning MN et al. High genotyping concordance between the digene HPV genotyping RH test and the reverse line blot genotyping assay on GP5+/6+-PCR products. J. Clin. Virol.46(Suppl. 3), S16–S20 (2009).
   Google Scholar
• Huang HJ, Huang SL, Lin CY et al. Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. Int. J. Gynecol. Cancer14(4), 639–649 (2004).
   PubMedGoogle Scholar
• Huang SL, Chao A, Hsueh S et al. Comparison between the Hybrid Capture II Test and an SPF1/GP6+ PCR-based assay for detection of human papillomavirus DNA in cervical swab samples. J. Clin. Microbiol.44(5), 1733–1739 (2006).
   PubMedGoogle Scholar
• Lin CY, Chen HC, Lin RW et al. Quality assurance of genotyping array for detection and typing of human papillomavirus. J. Virol. Methods140(1–2), 1–9 (2007).
   PubMedGoogle Scholar
• Lin CY, Chao A, Yang YC et al. Human papillomavirus typing with a polymerase chain reaction-based genotyping array compared with type-specific PCR. J. Clin. Virol.42(4), 361–367 (2008).
   PubMedGoogle Scholar
• Lai CH, Huang HJ, Hsueh S et al. Human papillomavirus genotype in cervical cancer: a population-based study. Int. J. Cancer120(9), 1999–2006 (2007).
   PubMedGoogle Scholar
• Chao A, Chang CJ, Lai CH et al. Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology – a population-based cohort study from Taiwan. Int. J. Cancer126(1), 191–198 (2010).
   PubMedGoogle Scholar
• Hesselink AT, Heideman DA, Berkhof J et al. Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening. J. Clin. Microbiol.48(3), 797–801 (2010).
   PubMedGoogle Scholar
• Jones J, Powell NG, Tristram A, Fiander AN, Hibbitts S. Comparison of the PapilloCheck DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set. J. Clin. Virol.45(2), 100–104 (2009).
   PubMedGoogle Scholar
• García-Sierra N, Martró E, Castellà E et al. Evaluation of an array-based method for human papillomavirus detection and genotyping in comparison with conventional methods used in cervical cancer screening. J. Clin. Microbiol.47(7), 2165–2169 (2009).
   PubMedGoogle Scholar
• Gomez-Roman JJ, Echevarria C, Salas S et al. A type-specific study of human papillomavirus prevalence in cervicovaginal samples in three different Spanish regions. APMIS117(1), 22–27 (2009).
   PubMedGoogle Scholar
• Sun ZR, Ji YH, Zhou WQ, Zhang SL, Jiang WG, Ruan Q. Characteristics of HPV prevalence among women in Liaoning province, China. Int. J. Gynaecol. Obstet.109(2), 105–109 (2010).
   PubMedGoogle Scholar
• Lin M, Yang LY, Li LJ, Wu JR, Peng YP, Luo ZY. Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust. NZ J. Obstet. Gynaecol.48(2), 189–194 (2008).
   PubMedGoogle Scholar
• Oh TJ, Kim CJ, Woo SK et al. Development and clinical evaluation of a highly sensitive DNA microarray for detection and genotyping of human papillomaviruses. J. Clin. Microbiol.42(7), 3272–3280 (2004).
   PubMedGoogle Scholar
• Erali M, Pattison DC, Wittwer CT, Petti CA. Human papillomavirus genotyping using an automated film-based chip array. J. Mol. Diagn.11(5), 439–445 (2009).
   PubMedGoogle Scholar
• Choi JJ, Kim C, Park H. Peptide nucleic acid-based array for detecting and genotyping human papillomaviruses. J. Clin. Microbiol.47(6), 1785–1790 (2009).
   PubMedGoogle Scholar
• Klug SJ, Molijn A, Schopp B et al. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J. Med. Virol.80(7), 1264–1274 (2008).
   PubMed Web of Science ®Google Scholar
• Hwang HS, Park M, Lee SY, Kwon KH, Pang MG. Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2,470 Korean women determined by DNA chip. Cancer Epidemiol. Biomarkers Prev.13(12), 2153–2156 (2004).
   PubMedGoogle Scholar
• Kim KH, Yoon MS, Na YJ, Park CS, Oh MR, Moon WC. Development and evaluation of a highly sensitive human papillomavirus genotyping DNA chip. Gynecol. Oncol.100(1), 38–43 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J. Clin. Microbiol.44(2), 504–512 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J. Clin. Microbiol.46(3), 1050–1059 (2008).
   PubMedGoogle Scholar
• Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J. Clin. Microbiol.48(1), 143–149 (2010).
   PubMedGoogle Scholar
• Oh Y, Bae SM, Kim YW et al. Polymerase chain reaction-based fluorescent Luminex assay to detect the presence of human papillomavirus types. Cancer Sci.98(4), 549–554 (2007).
   PubMed Web of Science ®Google Scholar
• Jiang HL, Zhu HH, Zhou LF, Chen F, Chen Z. Genotyping of human papillomavirus in cervical lesions by L1 consensus PCR and the Luminex xMAP system. J. Med. Microbiol.55(Pt 6), 715–720 (2006).
   PubMedGoogle Scholar
• Nazarenko I, Kobayashi L, Giles J, Fishman C, Chen G, Lorincz A. A novel method of HPV genotyping using Hybrid Capture sample preparation method combined with GP5+/6+ PCR and multiplex detection on Luminex XMAP. J. Virol. Methods154(1–2), 76–81 (2008).
   PubMedGoogle Scholar
• Wallace J, Woda BA, Pihan G. Facile, comprehensive, high-throughput genotyping of human genital papillomaviruses using spectrally addressable liquid bead microarrays. J. Mol. Diagn.7(1), 72–80 (2005).
   PubMedGoogle Scholar
• Geraets DT, Heideman DA, de Koning MN et al. High-throughput genotyping of high-risk HPV by the Digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology. J. Clin. Virol.46(Suppl. 3), S21–S26 (2009).
   Google Scholar
• Mammas IN, Sourvinos G, Vakonaki E, Giamarelou P, Michael C, Spandidos DA. Novel human papilloma virus (HPV) genotypes in children with recurrent respiratory papillomatosis. Eur. J. Pediatr.169(8), 1017–1021 (2010).
   PubMedGoogle Scholar
• Lie AK, Kristensen G. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert Rev. Mol. Diagn.8(4), 405–415 (2008).
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev.17(10), 2536–2545 (2008).
   PubMed Web of Science ®Google Scholar
• Molden T, Kraus I, Skomedal H, Nordstrøm T, Karlsen F. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J. Virol. Methods142(1–2), 204–212 (2007).
   PubMed Web of Science ®Google Scholar
• Lie AK, Risberg B, Borge B et al. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol. Oncol.97(3), 908–915 (2005).
   PubMed Web of Science ®Google Scholar
• Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J. Med. Virol.73(1), 65–70 (2004).
   PubMed Web of Science ®Google Scholar
• Keegan H, Mc Inerney J, Pilkington L et al. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J. Virol. Methods155(1), 61–66 (2009).
   PubMedGoogle Scholar
• Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol. Biomarkers Prev.14(2), 367–372 (2005).
   PubMed Web of Science ®Google Scholar
• Molden T, Nygard JF, Kraus I et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer114(6), 973–976 (2005).
   PubMed Web of Science ®Google Scholar
• Tropé A, Sjøborg K, Eskild A et al. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J. Clin. Microbiol.47(8), 2458–2464 (2009).
   PubMedGoogle Scholar
• Dockter J, Schroder A, Eaton B et al. Analytical characterization of the APTIMA HPV Assay. J. Clin. Virol.45(Suppl. 1), S39–S47 (2009).
   Web of Science ®Google Scholar
• Jeantet D, Schwarzmann F, Tromp J et al. NucliSENS EasyQ HPV v1 test – testing for oncogenic activity of human papillomaviruses. J. Clin. Virol.45(Suppl. 1), S29–S37 (2009).
   PubMed Web of Science ®Google Scholar
• Boulet GA, Micalessi IM, Horvath CA, Benoy IH, Depuydt CE, Bogers JJ. Nucleic acid-sequence based amplification assay for HPV mRNA detection and typing: evidence for DNA amplification. J. Clin. Microbiol.48(7), 2524–2529 (2010).
   PubMedGoogle Scholar
• Getman D, Aiyer A, Dockter J, Giachetti C, Zhang F, Ginocchio CC. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets. J. Clin. Virol.45 (Suppl. 1), S49–S54 (2009).
   Google Scholar
• Castle PE, Dockter J, Giachetti C et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin. Cancer Res.13(9), 2599–2605 (2007).
   PubMed Web of Science ®Google Scholar
• Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J. Clin. Virol.45(Suppl. 1), S55–S61 (2009).
   Google Scholar
• Cuschieri K, Kitchener H, Horne A et al. Clinical performance of a broad-spectrum RNA assay in a high-prevalence disease setting. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3–8 July 2010.
   Google Scholar
• Monsonego J, Hugens M, Zerat L et al. Comparison of the APTIMA HPV mRNA Assay with the Hybrid Capture 2 HPV DNA Assay and cytology in cervical cancer screening. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3–8 July 2010.
   Google Scholar
• Guo M, Gong Y, Deavers M et al. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J. Clin. Microbiol.46(1), 274–280 (2008).
   PubMedGoogle Scholar
• Kong CS, Balzer BL, Troxell ML, Patterson BK, Longacre TA. p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. Am. J. Surg. Pathol.31(1), 33–43 (2007).
   PubMedGoogle Scholar
• Mirasoli M, Guardigli M, Simoni P et al. Multiplex chemiluminescence microscope imaging of P16(INK4A) and HPV DNA as biomarker of cervical neoplasia. Anal. Bioanal. Chem.394(4), 981–987 (2009).
   PubMedGoogle Scholar
• Narimatsu R, Patterson BK. High-throughput cervical cancer screening using intracellular human papillomavirus E6 and E7 mRNA quantification by flow cytometry. Am. J. Clin. Pathol.123(5), 716–723 (2005).
   PubMed Web of Science ®Google Scholar
• Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J. Clin. Virol.32(Suppl. 1), S34–S42 (2005).
   Google Scholar
• Stoler MH, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am. J. Clin. Pathol.127(3), 335–337 (2007).
   PubMedGoogle Scholar
• Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev. Mol. Diagn.8(5), 599–605 (2008).
   PubMed Web of Science ®Google Scholar
• Grce M. Primary and secondary prevention of cervical cancer. Expert Rev. Mol. Diagn.9(8), 851–857 (2009).
   PubMed Web of Science ®Google Scholar
• Castle PE, Rodríguez AC, Burk RD et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. Br. Med. J.339, b2569 (2009).
   PubMedGoogle Scholar
• Arbyn M, Cuzick J. International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention. Cancer Lett.278(1), 1–2 (2009).
   PubMedGoogle Scholar
• Wilkinson DE, Baylis SA, Padley D et al. Establishment of the 1st WHO international standards for human papillomavirus type 16 DNA and type 18 DNA. Int. J. Cancer126(12), 2969–2983 (2010).
   PubMedGoogle Scholar
• Gök M, Heideman DA, van Kemenade FJ et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. Br. Med. J. 340:c1040 (2010).
   PubMedGoogle Scholar
• Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med.360(14), 1385–1394 (2009).
   PubMed Web of Science ®Google Scholar
• Schiffman M, Rodriguez AC, Chen Z et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res.70(8), 3159–3169 (2010).
   PubMed Web of Science ®Google Scholar
• Castle PE. New molecular markers for cervical cancer screening: distinguishing hype from hope. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3–8 July 2010.
   Google Scholar
• McCredie MR, Sharples KJ, Paul C et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol.9(5), 425–434 (2008).
   PubMed Web of Science ®Google Scholar
• Bosch FH. Editorial: The transition time for screening programs. HPV Today20, 2 (2010).
   Google Scholar